VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.74 USD
+0.08 (3.01%)
Updated May 23, 2024 10:54 AM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
VYNE Therapeutics Inc. [VYNE]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Seeds Are Sown For BETi Pipeline''s Clinical Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biomarker Results Reinforce VYN201''s MoA and Previous Positive Phase 1b Data; Phase 2b to Start in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Buoyed by Positive Initial Data, BETi Pipeline Progresses Through Clinical Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Fruits of Labor; KOL Event Spotlights VYNE''s Recent Clinical Development Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Positive Early Vitiligo Clinical Data and VYN202 Profile Building; Target Reduced to $5.75 on Significant Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; BETi Program Shows Signs of Blossoming; Topline Phase 1b Vitiligo Data in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; BETi Program Continues to Put Down Roots; VYN201 Phase 1b Data in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYNE''s Latest Harvest: VYN202 Joins the InhiBET Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201 Takes Root in Preclinical Model of IPF
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201''s Safety Profile Matures on the Vine; Top-Line Phase 1b Vitiligo Data in Mid-23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Project Strong BETi Visibility This Year; Favorable Safety a Great Start; Split-Adjusted Target to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VYN201 Continues to Bloom As First Vitiligo Patient Dosed in Phase 1a/b trial; Top-Line Data Expected 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Start of Phase 1a/b Sows the Seeds for VYN201''s Future Clinical Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Ready, Set, Go!; VYN201 About to Initiate Phase1 Vitiligo Trial in the Coming Weeks
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; BETi Program Readies For a Turn at Bat; Phase 1a/b in Vitiligo Slated to Begin in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FMX114 Misses in AD; Critical Shift Now to BETi Program; Target Reduced to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FMX114 Phase 2a Completes Enrollment Off of Positive Phase 1b Look; Top-Line Data Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Features InhiBET Platform; Vitiligo First Up For VYN201; FMX114 Phase 2a Data Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Recent Clinical Progress Prepares the Ground for an Active Pipeline in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: VYNE Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FMX114 Starts to Bloom With Additional Positive Phase 1b Data; Phase 2a Results Expected in 2Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J